Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer therapeutics - Daiichi Sankyo

Drug Profile

Research programme: cancer therapeutics - Daiichi Sankyo

Alternative Names: DS-5272

Latest Information Update: 21 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rigel Pharmaceuticals
  • Developer Daiichi Sankyo Company; Rigel Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Proto-oncogene protein c mdm2 inhibitors; Ubiquitin-protein ligase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 21 Nov 2017 Preclinical development for Cancer is ongoing in USA
  • 12 Dec 2016 Daiichi Sankyo forms a strategic partnership with DarwinHealth to prioritise investigational compounds based on tumour checkpoints for clinical development
  • 24 Nov 2015 Rigel Pharmaceuticals and Daiichi Sankyo enters into a collaboration for discovering and developing MDM2 inhibitors in Cancer (Rigel Pharmaceuticals pipeline) before November 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top